High dose aflibercept for treating neovascular age-related macular degeneration (nAMD)

High dose aflibercept is in development for the treatment of neovascular age-related macular degeneration (nAMD). nAMD is a condition that commonly affects people over the age of 50 and causes vision disturbance or blind spots in the centre of the visual field and progresses rapidly over several weeks or months without any treatment. Aflibercept is licensed at a lower concentration for the treatment for nAMD but the more concentrated high-dose version is expected to increase the time needed between doses while retaining the effectiveness in preventing further damage to vision.